Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
actinium Ac 225-FL-020
- Development stage
- Unknown
- Lead developer
- Full-Life Technologies
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Administration
- Intravenous
01
Overview
Actinium Ac 225-FL-020 is a next-generation, prostate-specific membrane antigen (PSMA)-targeted alpha radioconjugate (RDC) developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The drug consists of the PSMA-targeting vector FL-020 conjugated to the highly potent alpha-emitting radioisotope actinium-225. Discovered using Full-Life's proprietary UniRDC and Clear-X linker-chelator technologies, the conjugate is designed to optimize biodistribution by enhancing tumor uptake and retention while maintaining rapid systemic clearance. This targeted delivery of alpha radiation induces DNA double-strand breaks and tumor cell apoptosis while sparing radiosensitive healthy tissues, such as the salivary glands, thereby potentially widening the therapeutic window compared to beta-emitting radioligands.
- Other names
- actinium Ac 225-FL-020actinium Ac-225-FL-020
02
Targets
DNAPSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on actinium Ac 225-FL-020.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on actinium Ac 225-FL-020.